Trial Profile

A Randomized, Open-Label, Parallel-Design Pharmacokinetic and Pharmacodynamic Interaction Study of TNM002 and Adsorbed Tetanus Vaccine Administered Alone and Simultaneously Administered in Chinese Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Siltartoxatug (Primary) ; Tetanus vaccine Tianjin CanSino Biotechnology
Indications Tetanus
Focus Pharmacodynamics; Pharmacokinetics
Sponsors Trinomab Biotech; Zhuhai Trinomab Pharmaceutical

20 Nov 2025 According to Trinomab Pharmaceuticalmedia release, Trinomab Biotech has changed its name to Zhuhai Trinomab Pharmaceuticals.
30 Sep 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com